Orthofix Medical Inc. Announces Spine Leadership Realignment, Preliminary Q1 2026 Results, and Reaffirms 2026 Outlook

Key Highlights

• Spine leadership team realigned to accelerate growth and enhance execution, with elimination of the President, Global Spine Solutions role.
• Preliminary first quarter 2026 net sales of approximately \$196.7 million, showing modest growth.
• Full-year 2026 guidance reaffirmed:
  • Net sales expected between \$850 million and \$860 million.
  • Non-GAAP adjusted EBITDA guidance in the \$95 million to \$98 million range.
  • Positive free cash flow expected for 2026 (excluding legal settlements).
• Upcoming investor events and earnings call dates announced.

Detailed Report

Strategic Realignment of Spine Leadership

Orthofix Medical Inc. (NASDAQ:OFIX), a global leader in medical technology, announced a significant realignment of its Spine leadership structure as part of its strategy to accelerate profitable growth and sharpen execution across its commercial and innovation priorities.

The company has eliminated the role of President, Global Spine Solutions in order to streamline the organization, accelerate decision-making, and clarify leadership accountability. As a result, key spine division leaders now report directly to CEO Massimo Calafiore.

• Shaeffer Bannigan (Senior Vice President, Global Spinal Solutions) takes on an expanded role as Leader of Spinal Solutions, with responsibility for overall spine strategy, commercial operations, and portfolio innovation.
• Mark Sienkiewicz (Vice President, U.S. Sales) continues to lead spinal implant commercial execution with a focus on distributor expansion and onboarding.
• John Winge (Vice President, Spine Commercial Strategy) is charged with driving commercial strategies to accelerate the adoption and growth of the 7D FLASH™ Navigation System.
• Patrick Fisher, already head of Limb Reconstruction, now also leads the Biologics business, aiming to leverage synergies across complementary portfolio segments.

CEO Massimo Calafiore commented, “These updates further clarify leadership alignment and ownership across our Spine portfolio while strengthening coordination across our commercial, strategic, and enabling technology teams. By simplifying our structure and placing decision-making closer to execution, we believe we are better positioned to move faster, scale high-value opportunities, and deliver sustainable, profitable growth for our shareholders.”

Preliminary Q1 2026 Financial Results

• Preliminary, unaudited net sales for Q1 2026 were approximately \$196.7 million.
• Non-GAAP pro forma net sales (excluding discontinued M6 artificial cervical and lumbar disc products) were approximately \$196.4 million, representing a 0.4% increase on a reported basis and 3% constant currency growth compared to Q1 2025.
• Reported net sales for Q1 2025 were \$193.6 million; thus, the year-over-year reported increase was approximately 1.6%.
• The company notes the impact from the discontinuation of M6 product lines, which contributed minimally (\$0.3 million in Q1 2026 vs. \$4.4 million in Q1 2025).

*Pro forma net sales exclude the impact from discontinuation of the M6 product lines.

Note: These results are preliminary and unaudited, subject to quarter-end closing adjustments.

2026 Full-Year Outlook Reaffirmed

• Net sales guidance remains \$850–\$860 million, representing an implied year-over-year pro forma constant currency growth of approximately 5.5% at the midpoint.
• Non-GAAP adjusted EBITDA expected to be \$95–\$98 million, with an anticipated 70 basis points of margin expansion at the midpoint compared to 2025.
• Free cash flow expected to be positive for the full year, excluding any potential legal settlements.

CEO Calafiore emphasized, “Precise execution, faster decision-making and innovation is the focus for Orthofix in 2026. Our teams executed well to start the year, and we are proving our ability to create shareholder value. Our preliminary first quarter net sales reflect meaningful progress through recent distributor transitions as we gear up for new product launches later this year. With a clearer strategic focus, stronger leadership alignment, and an increased emphasis on high-value growth initiatives, we believe we are well positioned to scale our commercial engine, accelerate innovation, and deliver long-term value for our shareholders.”

Upcoming Investor Events

• 25th Annual Needham Virtual Healthcare Conference: Orthofix will participate in 1×1 meetings on April 14, 2026. Contact Needham or email [email protected] to register.
• Q1 2026 Earnings Call: Full financial results will be released on May 5, 2026, before market open, with a conference call and webcast at 8:30 am ET. Dial (888) 596-4144 (US) or (646) 968-2525 (international), ID 7578740. The webcast and materials will be posted at ir.Orthofix.com.

About Orthofix Medical Inc.

Orthofix is a global medical technology company headquartered in Lewisville, Texas, delivering a broad portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics, and enabling technologies such as the 7D FLASH™ Navigation System.

Investor Takeaways and Potential Price Sensitivities

• Organizational realignment could accelerate decision-making and improve operational execution, a potentially positive catalyst for future growth and profitability.
• Preliminary Q1 results indicate growth despite the discontinuation of the M6 product line, suggesting resilience and potential for market share gains.
• Reaffirmed 2026 guidance demonstrates management’s confidence in the business trajectory, which may support investor sentiment and share price stability.
• The positive outlook for free cash flow and margin expansion could be seen as favorable by investors seeking operational leverage and cash generation.
• Any deviation from these preliminary results or guidance in the final audited numbers, or unexpected developments in legal settlements, could impact the share price.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements, including those regarding Orthofix’s financial outlook, growth strategies, and market opportunities. Actual results may differ materially due to various risks and uncertainties, including but not limited to market acceptance of products, development and regulatory risks, competitive dynamics, supply chain factors, and legal matters. Readers are encouraged to review Orthofix’s filings with the SEC for a discussion of these and additional risks. No obligation is undertaken to update forward-looking statements as a result of new information or future events, except as required by law.

View Orthofix Medical Inc. Historical chart here